Alzheimer's disease: insights for risk evaluation and prevention in the Chinese population and the need for a comprehensive programme in Hong Kong/China

Hong Kong Med J. 2018 Oct;24(5):492-500. doi: 10.12809/hkmj187244.

Abstract

With the ageing of the global population, China is projected to be impacted significantly by the rising number of patients with Alzheimer's disease (AD). A cure for AD is not yet available, so society should be prepared for an increasing AD-related burden. In this review, we examine this impending problem and provide overviews on (a) the magnitude of the problem of AD in Hong Kong/China in the near future; (b) the genetic and lifestyle risk factors that contribute to AD; (c) current diagnostic approaches and the potential of newly discovered genetic biomarkers for early detection; (d) medications, non-pharmacological interventions, and possible preventive measures; and (e) the need for social and psychological care from the community. In Hong Kong, primary care and AD-related support for at-risk individuals, patients, and caregivers are inadequate. A joint effort from the medical community, government, universities, non-governmental organisations/charities, and industry should initiate the development of a long-term programme for AD. Finally, we outline recommendations for the relevant parties to consider.

Keywords: Alzheimer disease/prevention & control; Biomarkers; Disease progression; Risk factors.

Publication types

  • Review

MeSH terms

  • Aged
  • Alzheimer Disease / epidemiology*
  • Alzheimer Disease / etiology
  • Alzheimer Disease / prevention & control
  • Asian People
  • China / epidemiology
  • Early Diagnosis*
  • Female
  • Health Services for the Aged
  • Hong Kong / epidemiology
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Prevalence
  • Risk Factors